Redx Pharma temporarily stops RXC004 cancer trial

This article was originally published here

UK-based Redx Pharma is temporarily stopping the phase 1/2a clinical study of a cancer candidate, RXC004, to rectify the dose-escalation procedure and restart at a lower dose levels.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply